Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses some of the highlights of skin cancer research at ESMO 2021. Interesting trials included KEYNOTE-716 (NCT03553836) for adjuvant therapy in high-risk melanoma, RELATIVITY-047 (NCT03470922) for relatlimab and nivolumab in advanced melanoma, and SECOMBIT (NCT02631447) for the integration of BRAF inhibitors with immunotherapy. Another highlight was the research on treatment of brain metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.